Efficacy of Chondroitin Sulfate in Patients with Knee and Hip Osteoarthritis

Шарапова, Е. П.; Таскина, Е. А.; Кашеварова, Н. Г.; Алексеева, Л. И.; Лила, А. М.

doi:10.14412/1996-7012-2021-4-120-125

Cited by 2 publications

(1 citation statement)

References 27 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Среди препаратов ХС для инъекционного введения наилучшей степенью очистки и наибольшей доказательной базой характеризуется Хондрогард ® [39][40][41]. Метаанализ восьми клинических исследований (n=771, возраст 53,6±6,2 года) применения инъекционной формы препарата Хондрогард ® в комплексной терапии ОА подтвердил достоверные ассоциации между его использованием и снижением уровня боли по визуальной аналоговой шкале, индексов Лекена и WOMAС при встречаемости побочных эффектов, статистически значимо не отличимой от контроля [42].…”

Section: Review Articlesunclassified

Prospects for the use of chondroitin sulfate and glucosamine sulfate in the treatment of patients with obesity-associated osteoarthritis (metabolic syndrome)

2022

Self Cite

View full text Add to dashboard Cite

The relationship between the pathophysiology of osteoarthritis (OA) and metabolic disorders (metabolic syndrome, obesity) is provided not only by mechanical causes (increased body weight pressure on the joints). A complex of molecular mechanisms, which mediates OA effect on the development of obesity, was established. Excessive activity of toll receptors, the NF-κB cascade, and metabolic disorders of endogenous chondroitin sulfates (CS) lead to chronic inflammation and the development of a complex of comorbid pathologies, including OA, atherosclerosis, and obesity. The relationship between insulin resistance and CS metabolism is also mediated by impaired genomic DNA methylation. Exogenous CS and glucosamine sulfate (GS) used in the long-term treatment of OA also contribute to the inhibition of the pathophysiology of obesity. By inhibiting O-glucosamination of intranuclear proteins (i.e., p53), GS can accelerate lipolysis of visceral fat. Anti-inflammatory effects of CS and GS is associated with inhibition of toll receptors and NF-κB, increased levels of antioxidant enzymes, regulation of expression of fibroblast growth factor 21, activation of adenosine monophosphate-activated protein kinase, and inhibition of secretion of chemoattractant protein MCP-1 and pancreatic lipase. Positive effect of CS and its oligosaccharides exposure on the pathophysiology of metabolic disorders is associated not only with a decrease in inflammation and normalization of fat metabolism but also with an improvement in the state of the intestinal microbiota. Experimental and clinical studies confirm the effects of CS and GS on body mass control. CS and GS are effective and safe when used in patients with OA associated with metabolic syndrome and/or obesity.

show abstract

Section: Review Articlesunclassified

Prospects for the use of chondroitin sulfate and glucosamine sulfate in the treatment of patients with obesity-associated osteoarthritis (metabolic syndrome)

2022

Self Cite

View full text Add to dashboard Cite

show abstract

Chondroitin sulfate in therapy osteoarthritis chronic pain patients according to actual clinical recommendations

Shavlovskaya

2021

Terapevticheskii arkhiv

View full text Add to dashboard Cite

Of undoubted interest is the search for new drugs comparable in effectiveness to nonsteroidal anti-inflammatory drugs (NSAIDs), but with a safer application profile. NSAIDs are characterized by a good analgesic effect due to the modulation of prostaglandin metabolism by inhibition of cyclooxygenase-2. One of the promising directions of pharmacotherapy of degenerative-dystrophic joint lesions is the use of symptom-modifying drugs of delayed action, which include chondroitin sulfate (CS). CS has antiresorptive activity, anti-inflammatory and anti-inflamaging effects. In addition to the direct effect on pain syndrome severity, he also have a modulating level effect of systemic inflammation of cartilage tissue. According to experts of international and Russian societies, pharmaceutical prescription-quality CS is a basic part of the treatment of osteoarthritis. One of the advantages of CS over NSAIDs is the preservation of the effect for 24 months after the treatment. Against the background of the use of CS, it is possible to reduce the dose or completely cancel NSAIDs, which helps to reduce the frequency of adverse events associated with their intake. CS has a favorable safety profile, which is important for elderly patients and those with comorbid diseases (cardioprotective effects). CS drugs can be administered per orally, intramuscularly, intra-articularly and in combination with different administration methods. Several clinical trials of CS (Chondrogard), including randomized, were conducted in Russia. The Russia Health Ministry approved the appointment of parenteral CS in clinical guidelines: Chronic pain in elderly and senile patients (2020), Falls in elderly and senile patients(2020), "Knee osteoarthritis" (2021), "Hip osteoarthritis" (2021).

show abstract

Efficacy of Chondroitin Sulfate in Patients with Knee and Hip Osteoarthritis

Cited by 2 publications

References 27 publications

Prospects for the use of chondroitin sulfate and glucosamine sulfate in the treatment of patients with obesity-associated osteoarthritis (metabolic syndrome)

Prospects for the use of chondroitin sulfate and glucosamine sulfate in the treatment of patients with obesity-associated osteoarthritis (metabolic syndrome)

Chondroitin sulfate in therapy osteoarthritis chronic pain patients according to actual clinical recommendations

Contact Info

Product

Resources

About